Spyre Therapeutics granted stock options to non-executive employees under inducement plan

From GlobeNewswire: 2025-07-03 16:05:00

Spyre Therapeutics, Inc. announced the approval of stock options for four non-executive employees under the 2018 Equity Inducement Plan. Each employee was granted options to purchase 121,600 shares of common stock with a 10-year term and an exercise price of $15.49. The options vest quarterly and monthly, contingent on continuous service with Spyre. Spyre Therapeutics focuses on developing next-generation IBD and immune-mediated disease products using antibody engineering and therapeutic combinations. For more information, visit www.spyre.com. For investor inquiries, contact Eric McIntyre, VP of Finance and Investor Relations at [email protected].



Read more at GlobeNewswire: Spyre Therapeutics Announces Grants of Inducement Awards